newsfilter
← Latest News
ClinicalTrials.gov·

A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants - NCT05288829

Incidence Of Treatment-Emergent Adverse Events, Absolute Bioavailability Of ALXN1210 SC, Percent Change From Baseline In Free Complement Component 5 (C5) At Day 8, (and 2 more...)